JP2003523971A5 - - Google Patents

Download PDF

Info

Publication number
JP2003523971A5
JP2003523971A5 JP2001556256A JP2001556256A JP2003523971A5 JP 2003523971 A5 JP2003523971 A5 JP 2003523971A5 JP 2001556256 A JP2001556256 A JP 2001556256A JP 2001556256 A JP2001556256 A JP 2001556256A JP 2003523971 A5 JP2003523971 A5 JP 2003523971A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001556256A
Other languages
Japanese (ja)
Other versions
JP2003523971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/031484 external-priority patent/WO2001056565A1/en
Publication of JP2003523971A publication Critical patent/JP2003523971A/ja
Publication of JP2003523971A5 publication Critical patent/JP2003523971A5/ja
Pending legal-status Critical Current

Links

JP2001556256A 2000-02-03 2000-11-16 C−4カーボネートタキサン Pending JP2003523971A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17996500P 2000-02-03 2000-02-03
US60/179,965 2000-02-03
PCT/US2000/031484 WO2001056565A1 (en) 2000-02-03 2000-11-16 C-4 carbonate taxanes

Publications (2)

Publication Number Publication Date
JP2003523971A JP2003523971A (ja) 2003-08-12
JP2003523971A5 true JP2003523971A5 (enExample) 2005-12-22

Family

ID=22658728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001556256A Pending JP2003523971A (ja) 2000-02-03 2000-11-16 C−4カーボネートタキサン

Country Status (20)

Country Link
US (1) US6750246B1 (enExample)
EP (1) EP1251846B1 (enExample)
JP (1) JP2003523971A (enExample)
AT (1) ATE273005T1 (enExample)
AU (1) AU778284B2 (enExample)
CA (1) CA2399116A1 (enExample)
CZ (1) CZ20022956A3 (enExample)
DE (1) DE60012988T2 (enExample)
DK (1) DK1251846T3 (enExample)
ES (1) ES2226954T3 (enExample)
HK (1) HK1047891B (enExample)
MY (1) MY129310A (enExample)
NZ (1) NZ521136A (enExample)
PE (1) PE20020747A1 (enExample)
PT (1) PT1251846E (enExample)
RU (1) RU2243223C2 (enExample)
TR (1) TR200402454T4 (enExample)
TW (2) TWI245042B (enExample)
WO (1) WO2001056565A1 (enExample)
ZA (1) ZA200207037B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
US7063977B2 (en) * 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
CA2470826A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US20070105944A1 (en) * 2002-10-25 2007-05-10 Comezoglu S N Taxane metabolites
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006058121A1 (en) * 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
US20060258736A1 (en) * 2005-05-12 2006-11-16 Bristol-Myers Squibb Company Dosing regimen
US20080221135A1 (en) * 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
MX352661B (es) 2009-11-05 2017-12-04 Rhizen Pharmaceuticals S A Star Moduladores novedosos de benzopiran cinasa.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110249A (en) 1989-05-31 1998-03-31 Univ Florida State Method for preparation of taxol using beta lactam
US5284864A (en) 1991-09-23 1994-02-08 Florida State University Butenyl substituted taxanes and pharmaceutical compositions containing them
US5399726A (en) 1993-01-29 1995-03-21 Florida State University Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
US6521660B2 (en) 1991-09-23 2003-02-18 Florida State University 3′-alkyl substituted taxanes and pharmaceutical compositions containing them
US6335362B1 (en) 1991-09-23 2002-01-01 Florida State University Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
HU0203995D0 (en) 1992-12-23 2003-04-28 Bristol Myers Squibb Co Oxazole derivatives for synthesis of sidechain-bearing taxanes and preparation thereof
US5475011A (en) * 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2192373A1 (en) 1994-06-09 1995-12-14 Hirofumi Terasawa Deacetoxytaxol derivative
FR2721024B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2726272B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5840929A (en) 1995-04-14 1998-11-24 Bristol-Myers Squibb Company C4 methoxy ether derivatives of paclitaxel
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5739359A (en) * 1997-01-24 1998-04-14 Virginia Tech Intellectual Properties, Inc. Methods for preparing 1-deoxy paclitaxels
HUP0101457A3 (en) 1997-12-31 2003-01-28 Bristol Myers Squibb Co Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them
KR100648125B1 (ko) 1999-05-17 2006-11-24 브리스톨-마이어스스퀴브컴파니 파클리탁셀 (탁솔 (Taxol, 등록상표)) 및 파클리탁셀유사체 제조에서 실릴 에테르의 절단을 위한 신규 반응조건
ATE266015T1 (de) 1999-08-11 2004-05-15 Bristol Myers Squibb Co Verfahren zur herstellung eines c-4- methylcarbonat-analogons von paclitaxel
BR0015149A (pt) 1999-10-27 2002-10-29 Baker Norton Pharma Método e composições para administração de taxanos oralmente a pacientes humanos
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
NZ539046A (en) 2001-01-18 2006-11-30 Pharmacia & Upjohn Co Llc Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability
UY27185A1 (es) 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
DE10154464B4 (de) 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Similar Documents

Publication Publication Date Title
BE2013C060I2 (enExample)
BE2013C048I2 (enExample)
BE2009C057I2 (enExample)
BE2011C032I2 (enExample)
BE2010C018I2 (enExample)
JP2003523817A5 (enExample)
BE2011C041I2 (enExample)
JP2001344724A5 (enExample)
JP2003523971A5 (enExample)
JP2001156641A5 (enExample)
JP2003508857A5 (enExample)
DE60144151D1 (enExample)
JP2001115858A5 (enExample)
BRPI0113372A8 (enExample)
JP2001339996A5 (enExample)
BR0112866A2 (enExample)
JP2005234607A5 (enExample)
JP2001268696A5 (enExample)
CN3136262S (enExample)
AU2000271150A8 (enExample)
CN3135584S (enExample)
CN3142146S (enExample)
CN3134619S (enExample)
CN3137238S (enExample)
CN3137601S (enExample)